GLP1R and obesity disorder: Increasing the therapeutic potential and reducing the side effects of U.S. Food and Drug Administration–approved glucagon-like peptide-1 receptor (GLP-1R) agonists used to treat obesity require complete characterization of the central mechanisms that mediate both the food intake-suppressive and illness-like effects of GLP-1R signaling.